newsfilter
← Latest News
Business Wire·

Covidien Announces Nine-Month Results of DURABILITY Iliac Study, Addition of Iliac Indication for EverFlex™ Stent System at VIVA 2014

LAS VEGAS--(BUSINESS WIRE)--Covidien plc (NYSE: COV) today announced nine-month results of the DURABILITY Iliac study and addition of the iliac indication for its EverFlex™ stent at the Vascular Interventional Advances (VIVA) 2014 conference. The nine-month results confirm the safety and effectiveness of the EverFlex™ and Protégé™ GPS™ self-expanding stent systems* for the treatment of lesions of the common and external iliac arteries.